No House member has disclosed a VKTX trade since 2025.
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 30, 2026 | Kelly-Gemmell Dorothy ElizabethDirector | Stock Award(Grant) at price 0.00 per share. | 6.3K | — |
| Jul 28, 2026 | Lian BrianChief Executive Officer | Sale at price 33.32 per share. | 148.5K | $4.95M |
| Jul 28, 2026 | Mancini MariannaChief Operating Officer | Sale at price 33.47 per share. | 18.2K | $609.64K |
| Jul 28, 2026 | Zante Gregory SChief Financial Officer | Sale at price 33.47 per share. | 21.2K | $710.14K |
| Jul 27, 2026 | Zante Gregory SChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 31.7K | — |
| Jul 27, 2026 | Lian BrianChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 221.7K | — |
| Jul 27, 2026 | Mancini MariannaChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 31.7K | — |
| Mar 9, 2026 | Aubuchon Neil WilliamOfficer | Purchase at price 33.50 per share. | 4.5K | $149.91K |
| Jan 4, 2026 | Lian BrianChief Executive Officer | Sale at price 32.29 - 35.07 per share. | 233.4K | $7.69M |
| Jan 4, 2026 | Mancini MariannaChief Operating Officer | Sale at price 32.29 - 35.07 per share. | 57.7K | $1.90M |
| Jan 4, 2026 | Zante Gregory SChief Financial Officer | Sale at price 32.09 - 34.24 per share. | 57.7K | $1.90M |
| Jan 1, 2026 | Foehr Matthew WDirector | Stock Award(Grant) at price 0.00 per share. | 3.1K | — |
| Jan 1, 2026 | Singleton J MatthewDirector | Stock Award(Grant) at price 0.00 per share. | 3.1K | — |
| Jan 1, 2026 | Zante Gregory SChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 73K | — |
| Jan 1, 2026 | Rowland Charles A JrDirector | Stock Award(Grant) at price 0.00 per share. | 3.1K | — |
| Jan 1, 2026 | Macartney LawsonDirector | Stock Award(Grant) at price 0.00 per share. | 3.1K | — |
| Jan 1, 2026 | Lian BrianChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 302.5K | — |
| Jan 1, 2026 | Rouan Sarah KathrynDirector | Stock Award(Grant) at price 0.00 per share. | 3.1K | — |
| Jan 1, 2026 | Mancini MariannaChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 73K | — |
| Jan 1, 2026 | Foehr Matthew WDirector | Sale at price 35.11 per share. | 16K | $561.69K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -17.5 | 16.5 | -3.8 | -4.2 | 5.0 | 19.2 | -18.6 | 3.3 | -0.5 | -13.1 | −19.4% | ||
| 2025 | -18.6 | -11.8 | -16.3 | 19.5 | -7.2 | -1.1 | 22.9 | -16.9 | -2.8 | 44.9 | -3.3 | -4.4 | −12.6% |
| 2024 | 29.7 | 219.2 | 6.4 | -3.0 | -21.8 | -14.9 | 7.5 | 12.5 | -1.3 | 14.6 | -27.0 | -24.0 | +116.2% |
| 2023 | -6.8 | 25.7 | 51.2 | 28.0 | 3.1 | -26.2 | -10.5 | -4.8 | -19.8 | -11.4 | 24.6 | 52.3 | +98.0% |
| 2022 | -19.3 | -9.7 | -10.4 | -20.7 | -6.7 | 30.2 | 4.2 | 5.6 | -14.5 | 50.7 | -1.2 | 132.1 | +104.3% |
| 2021 | 29.8 | -7.8 | -6.2 | 1.0 | -18.0 | 14.3 | 2.7 | 7.5 | -5.0 | -7.3 | -8.8 | -13.4 | −18.3% |
| 2020 | -21.7 | -5.7 | -20.9 | 23.1 | 24.1 | 0.8 | -2.6 | -4.7 | -13.0 | -3.3 | 14.2 | -12.4 | −29.8% |
| 2019 | 6.7 | 3.1 | 18.2 | -21.2 | -1.8 | 7.9 | -7.3 | -9.6 | -1.0 | -6.0 | 13.1 | 9.6 | +4.8% |
| 2018 | 30.8 | 17.9 | -30.2 | -5.7 | 142.5 | -5.0 | 7.5 | 28.1 | 33.3 | -21.9 | -17.0 | -32.2 | +88.4% |
| 2017 | 18.5 | 8.5 | -4.6 | -4.1 | -15.7 | -8.5 | -2.8 | -1.0 | 83.7 | 24.6 | 27.7 | 33.6 | +241.2% |
| 2016 | -39.0 | -13.0 | -21.5 | 2.1 | -4.8 | -8.7 | 11.1 | -4.3 | 4.6 | -23.6 | 0.9 | 10.2 | −65.1% |
| 2015 | -6.5 | -13.2 | -14.7 | 1.0 | -4.7 | -3.8 | -43.3 | 6.6 | −61.2% |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Buy / hold / sell counts